The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetics (PK) of eribulin mesylate in cancer patients (pts) with normal and impaired renal function.
Antoinette R. Tan
Research Funding - Eisai
John Sarantopoulos
No relevant relationships to disclose
Lucy Lee
Employment or Leadership Position - Eisai
Larisa Reyderman
Employment or Leadership Position - Eisai
Yi He
Employment or Leadership Position - Eisai
Martin S. Olivo
Employment or Leadership Position - Eisai
Sanjay Goel
Research Funding - Eisai